Skip to main content
. Author manuscript; available in PMC: 2018 Jul 15.
Published in final edited form as: J Immunol. 2017 Jun 7;199(2):806–815. doi: 10.4049/jimmunol.1700231

FIGURE 1. 64Cu-LLP2A and 18F-FDG are retained in inflamed mouse paws following CFA injection.

FIGURE 1

(A) PET/CT comparison of 64Cu-LLP2A and 18F-FDG uptake in injected (right) and uninjected (left) mouse paws. PET signal is indicated in Table 1. Note that 64Cu-LLP2A is taken up by lymph nodes distal to the site of injection whereas lymph nodes are not visible in the 18F-FDG-probed animal at 45 min post injection. The difference in scan times for 64Cu-LLP2A and 18F-FDG scan times reflects the different pharmacokinetics of these probes. (B) In vivo fluorescence image showing accumulation of LLP2A-Cy5 in the injected paw (right) compared to uninjected paw (left). (C) Flow cytometry on cells collected from the inflamed paw from animal injected with LLP2A-Cy5 or not (control) demonstrates neutrophils, macrophages, and T cells stain positively with Cy5-labeled LLP2A (red lines). Black lines represent control animals not injected with LLP2A-Cy5.